TIMP2 and osteosarcoma: Our analyses showed that the rs2277698 in the TIMP2 was associated with a 0.64-fold decreased the osteosarcoma risk under the co-dominant model (OR = 064, 95% CI = 0.43–0.83, P = .012 for the “T/T” genotype), 0.56-fold decreased the osteosarcoma risk under the dominant model (OR = 0.56, 95% CI = 0.21–0.92, P = .004 for the “C/T-T/T” genotype), and 0.36-fold decreased the osteosarcoma risk under the Log-additive model (OR = 0.36, 95% CI = 0.29–0.89, P = 0.039), respectively.